Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;52(4):512-20.
doi: 10.1002/mus.24569. Epub 2015 Mar 31.

Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy

Doris G Leung  1   2 , John A Carrino  3   4 , Kathryn R Wagner  1   2   5 , Michael A Jacobs  3   6
Affiliations

Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy

Doris G Leung et al. Muscle Nerve. 2015 Oct.

Abstract

Introduction: Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary disorder that causes progressive muscle wasting. Increasing knowledge of the pathophysiology of FSHD has stimulated interest in developing biomarkers of disease severity.

Methods: Two groups of MRI scans were analyzed: whole-body scans from 13 subjects with FSHD; and upper and lower extremity scans from 34 subjects with FSHD who participated in the MYO-029 clinical trial. Muscles were scored for fat infiltration and edema-like changes. Fat infiltration scores were compared with muscle strength and function.

Results: The analysis revealed a distinctive pattern of both frequent muscle involvement and frequent sparing in FSHD. Averaged fat infiltration scores for muscle groups in the legs correlated with quantitative muscle strength and 10-meter walk times.

Conclusions: Advances in MRI technology allow for acquisition of rapid, high-quality, whole-body imaging in diffuse muscle disease. This technique offers a promising disease biomarker in FSHD and other muscle diseases.

Keywords: FSHD; MRI; facioscapulohumeral muscular dystrophy; radiographic biomarkers; whole-body imaging.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Heat map (A) of all 1330 muscles scored in 13 individuals with FSHD. Subjects are arranged (left to right) from lowest to highest mean MRI score. Muscles on the left and right sides of the body are placed to the left and right sides (respectively) of the labeled tick marks for each subject. Fat infiltration scores on T1-weighted MRI (from 0 to 5) and their corresponding colors are shown in the numbered bar on the right. The mean MRI score for all muscles scored within a single individual are represented in the bottom row. Muscles are listed in a superior to inferior arrangement, corresponding to the anatomic regions defined by the composite coronal MR image on the right (B).
Figure 2
Figure 2
Fitted regression lines for muscle strength in 5 muscle groups and 10-meter walk time against mean fat infiltration MRI score in specific muscle groups in subjects scanned using whole-body MRI.
Figure 3
Figure 3
Fitted regression lines for muscle strength against mean fat infiltration scores on MRI score in specific muscles groups in participants from the MYO-029 trial.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. Journal of child neurology. 2008;23(8):883–8. - PubMed
    1. Economics A Association MD. The Cost of Muscular Dystrophy. Access Economics; 2007.
    1. Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle & nerve. 2014;49(3):431–8. - PubMed
    1. Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord. 2008;18(11):894–903. - PubMed
    1. Mazzone ES, Vasco G, Palermo C, Bianco F, Galluccio C, Ricotti V, et al. A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Developmental medicine and child neurology. 2012;54(10):879–85. - PubMed

Publication types